ClinicalTrials.gg
RecruitingNCT04288999JCOG1801Updated Jun 4, 2020

Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer

A Phase 3 interventional study of Chemotherapy and Preoperative radiotherapy in Rectal Cancer Recurrent, sponsored by National Cancer Center Hospital East. Recruiting at 45 sites in Japan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-06-04.

Sponsored by National Cancer Center Hospital East · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Registered 4 months after the study started (first participant enrolled Oct 2019, registered Feb 2020).
  • Started Oct 2019; still recruiting 7 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Rectal Neoplasms with a site in Japan — 7 open to participants now, 12 under way, 5 of them phase 3. Rectal Neoplasms · Japan.

Planned enrollment
11th of 24
110 · median 105
Started
2019
the only one that year
Phase 3
8 of 26
4 open now
Primary completion
2025-08
later than 1 of 11 live
Registered
15th of 26
by date
Lead sponsor
2 of 26
National Cancer Center Hospital East

Among the 26 studies in Rectal Neoplasms with a site in Japan, this one is the 11th largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2019, is one of 8 in phase 3, reaches primary completion later than 1 of the 11 other live ones, and was the 15th registered.

Rectal Neoplasms

2,403 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

7 of the 26 studies in Rectal Neoplasms with a site in Japan are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Rectal Neoplasms with a site in Japan, or all of them as a file.
02

Study summary

JCOG1801 is a randomized phase III trial which was initiated in Japan in August 2019 to confirm the superiority of preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy for local relapse-free survival over standard treatment, i.e. surgery plus adjuvant chemotherapy, for previously non-irradiated locally recurrent rectal cancer.

Read the detailed description

In all, 110 patients from 43 Japanese institutions will be recruited over a period of 6 years. Eligible patients would be registered and randomly assigned to each group with an allocation ratio of 1:1. The primary endpoint is local relapse-free survival. The secondary endpoints are overall survival, relapse-free survival, proportion of local relapse, proportion of distant relapse, proportion of patients with pathological R0 resection, response rate of preoperative chemoradiotherapy (preoperative chemoradiotherapy arm), pathological complete response rate (preoperative chemoradiotherapy arm), proportion of patients who completed the protocol treatment, incidence of adverse events (adverse reactions), and quality of life after surgery.

03

Conditions studied

  • Rectal Cancer Recurrent

Browse trials for

Keywords

  • Rectal cancer
  • Locally recurrent rectal cancer
  • Chemoradiotherapy
  • Surgery
  • Chemotherapy
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histopathologically proven adenocarcinoma or adenosquamous carcinoma on the resected specimen of the initial rectal cancer or endoscopic from the initial rectal cancer.
  2. The main tumor location of the initial rectal cancer is upper, middle or lower rectum, or anal canal.
  3. Either of the following treatments was performed for the initial rectal cancer, and classified as R0/1 or ER (Endoscopical R)0/1 on pathological diagnosis.

    i) Surgical resection (including local resection, with or without lymph node dissection).

    ii) Endoscopic resection.

  4. Patients with distant during or after treatment for the initial rectal cancer, and radical surgical resection or radical radiotherapy performed more than 168 days before registration is eligible.
  5. Recurrent rectal cancer diagnosed by any of the following modalities after treatment for the initial rectal cancer.

    i) The recurrent lesion is diagnosed. ii) Diagnosed as local recurrence by more than two modalities among contrast-enhanced CT, contrast-enhanced MRI, or positron emission computed tomography (PET).

    iii) Chronological progression of the lesion seen on more than one modality among contrast-enhanced CT, MRI, or PET.

  6. The main tumor location is within pelvis as seen on contrast-enhanced CT and MRI if recurrent lesion is multiple, or recurrent lesions spread outside of pelvis continuously.
  7. LRRC is diagnosed with no following condition. i) Judged as resectable endoscopically. ii) Depth of invasion within the muscularis propria as seen on contrast-enhanced CT, MRI, or PET in case of recurrence inside the intestine iii) Solitary ovarian metastasis. iv) Recurrence of the common iliac lymph node alone.
  8. LRRC is diagnosed as resectable, and all the following conditions must be fulfilled:

    i) No distant metastasis on contrast-enhanced CT (cM0). ii) Estimated circumferential resection margin >0 mm. iii) Leg amputation not required. iv) Preservation of the first sacral nerve possible.

  9. No prior surgery for recurrent rectal cancer.
  10. No prior pelvic irradiation for any .
  11. A patient who has received systemic chemotherapy for any malignancies and the final dose was administered more than 14 days ago.
  12. Age at registration is 20 to 80 years old.
  13. (ECOG) performance status is 0 or 1.
  14. is not mandatory.
  15. Adequate oral intake.
  16. Sufficient organ function. i) >= 1,500/mm3 ii) >= 9.0 g/dL iii) count >= 100,000/mm3 iv) Total =\< 2.0 mg/dL v) (AST) =\< 100 U/L vi) Alanine Aminotransferase (ALT) =\< 100 U/L vii) Cr =\< 1.5 mg/dL
  17. Open surgery or laparoscopic surgery is planned.
  18. Written is obtained.

Exclusion criteria

Exclusion Criteria:

  1. Synchronous or metachronous (within 5 years) except cancer with 5-year relative survival rate of 95% or more such as carcinoma in situ, intramucosal tumor, or early stage cancers.
  2. Infections requiring systemic treatment.
  3. Body temperature higher than 38 degrees Celsius at registration.
  4. Pregnant female, female within 28 days post-parturition, or lactating mother. Men with partners planning conception in the near future.
  5. Severe psychological disease.
  6. Continuous systemic or treatment.
  7. Uncontrollable diabetes mellitus.
  8. Uncontrollable hypertension.
  9. Unstable angina pectoris, or history of myocardial infarction within 6 months.
  10. Uncontrollable valvular disease, dilated cardiomyopathy, or hypertrophic cardiomyopathy.
  11. Positive serum (HB)s antigen or serum Virus (HCV) antibody.
  12. Positive serum antibody.
  13. Interstitial pneumonia, pulmonary fibrosis, or severe emphysema on chest CT.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Arm A

    Preoperative chemoradiotherapy (CRT) followed by Surgery plus Adjuvant chemotherapy Preoperative CRT: capecitabine (1650 mg/m2/day) and radiotherapy (50.4 Gy/28 Fr) Adjuvant chemotherapy: CAPOX (capecitabine+oxaliplatin) or mFOLFOX6 (5-fluorouracil+l-leucovorin+oxaliplatin) or capecitabine or 5-fluorouracil (FU) +l-leucovorin (LV) CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14) mFOLFOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours. Capecitabine: 2000 mg/m2/day, twice daily, days 1-14 5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours

    Drug: Chemotherapy · Radiation: Preoperative radiotherapy · Other: Procedure

  • Active comparator
    Arm B

    Surgery plus Adjuvant chemotherapy Adjuvant chemotherapy: CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14) mFOLFOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours. Capecitabine: 2000 mg/m2/day, twice daily, days 1-14 5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours

    Drug: Chemotherapy · Other: Procedure

Interventions

  • DrugChemotherapy

    Adjuvant chemotherapy: CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14) mFOLOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours. Capecitabine: 2000 mg/m2/day, twice daily, days 1-14 5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours

    Also known as: CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV

  • RadiationPreoperative radiotherapy

    Preoperative chemoradiotherapy (CRT) followed by Surgery plus Adjuvant chemotherapy Preoperative CRT: capecitabine (1650 mg/m2/day) and radiotherapy (50.4 Gy/28 Fr)

    Also known as: Capecitabine plus radiotherapy

  • OtherProcedure

    Surgery for Locally Recurrent Rectal Cancer (LRRC) will be performed within 42 days from registration for the patients in arm A, and between days 56 and 98 from the completion of the preCRT for the patients in arm B. Appropriate surgical procedure will be performed to achieve R0 resection, such as low anterior resection, super low anterior resection, intersphincteric resection, Hartmann procedure, rectal amputation, pelvic exenteration, tumor resection, or lateral lymph node dissection

    Also known as: Surgery

06

What researchers measure

Primary outcomes

  1. Locally recurrent free survival

    the period from registration in the trial to either the first event of local relapse or death from any cause and censored at the last date of contact for a living patient

    Time frame: 3-years after registration

Secondary outcomes

  1. Overall survival (OS)

    s the time from registration to death from any cause and censored at the last date of contact for a living patient

    Time frame: 3-years after registration

  2. Recurrence free survival (RFS)

    the time from registration to either the first incidence of relapse or death from any cause and censored at the last date of contact for a living patient

    Time frame: 3-years after registration

  3. Local relapse rate

    Proportion of local relapse

    Time frame: 3-years after registration

  4. Distant relapse rate

    Proportion of distant relapse

    Time frame: 3-years after registration

  5. R0 resection rate

    Proportion of patients with pathological R0 resection

    Time frame: 1 month after surgery

  6. Response rate of preoperative chemoradiotherapy (preCRT)

    Response rate of preCRT (arm B)

    Time frame: before surgery

  7. Pathological complete response rate

    Pathological complete response rate (arm B)

    Time frame: 1 month after surgery

  8. Completeness of the protocol treatment

    Proportion of patients who completed the protocol treatment

    Time frame: 8 months after surgery

  9. Adverse event rate

    Incidence of adverse events (adverse reactions)

    Time frame: 3-years after surgery registration

  10. QOL

    QOL after surgery based on the Trial Outcome Index-Physical/Functional/Colorectal (TOI-PFC) \[0(better)-84(worse)\]

    Time frame: 3-years after registration

07

Study locations

40 of 45 sites recruiting
08

References and documents

Publications

  • Kadota T, Tsukada Y, Ito M, Katayama H, Mizusawa J, Nakamura N, Ito Y, Bando H, Ando M, Onaya H, Fukuda H, Kanemitsu Y. A phase III randomized controlled trial comparing surgery plus adjuvant chemotherapy with preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy for locally recurrent rectal cancer: Japan Clinical Oncology Group study JCOG1801 (RC-SURVIVE study). Jpn J Clin Oncol. 2020 Aug 4;50(8):953-957. doi: 10.1093/jjco/hyaa058. PubMed 32409830 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2019 (actual). Primary completion is estimated for Aug 2025, 70 months after the start.

Of 73 non-industry phase 3 interventional studies under Rectal Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 104. This study's planned 70 months is close to that.

Counting every sponsor, half of 81 studies reached it within 59 months; a quarter within 37 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2020
First posted
Feb 28, 2020
StartActual
Oct 1, 2019
Primary completionEst.
Aug 2025
CompletionEst.
Oct 2028
Last update
Jun 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04288999
Lead sponsor
National Cancer Center Hospital East
Collaborators
Japan Clinical Oncology Group, Japan Agency for Medical Research and Development
Responsible party
Sponsor
First posted
Feb 28, 2020
Start date
Oct 1, 2019
Primary completion
Aug 2025 (estimated)
Completion
Oct 2028 (estimated)
Last update
Jun 4, 2020

Study contacts

Yuichiro Tsukada, MD,PhD
Contact
yutsukad@east.ncc.go.jp
+80-4-7133-1111
Masaaki Ito, MD, PhD
Contact
maito@east.ncc.go.jp
+80-4-7133-1111
Masaaki Ito, MD, PhD
principal investigator · National Cancer Center Hospital East

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion